Citigroup Inc Scynexis Inc Transaction History

Citigroup Inc

$217 Billion
Q3 2025

A detailed history of Citigroup Inc transactions in Scynexis Inc stock. As of the latest transaction made, Citigroup Inc holds 6,282 shares of SCYX stock, worth $3,706. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,282

Holding current value

$3,706

% of portfolio

0.0%

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 10, 2025	BUY	$0.68 - $1.19 $4,271 - $7,475	6,282 New	6,282 $5,000
Q2 2022 Aug 10, 2022	SELL	$1.77 - $3.87 $11,609 - $25,383	-6,559 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$3.56 - $6.66 $23,350 - $43,682	6,559 New	6,559 $26,000

Others Institutions Holding SCYX

# of Institutions

Shares Held

12.5M

Call Options Held

Put Options Held

Avidity Partners Management LP Dallas, TX

3.35M
Shares

$1.98 Million
1.43% of portfolio
Kingdon Capital Management, L.L.C. New York, NY

2.24M
Shares

$1.32 Million
0.28% of portfolio
Vanguard Group Inc Valley Forge, PA

1.76M
Shares

$1.04 Million
0.0% of portfolio
Federated Hermes, Inc. Pittsburgh, PA

1.58M
Shares

$934,175
0.0% of portfolio
Decheng Capital Management Iii (Cayman), LLC

556K
Shares

$327,777
0.7% of portfolio

View Full List

About SCYNEXIS INC

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $19.3M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

More about SCYX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account